* 10X Genomics Inc reported a quarterly adjusted loss of 30 cents​​ per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of -79 cents. The mean expectation of nineteen analysts for the quarter was for a loss of 34 cents per share. Wall Street expected results to range from -57 cents to -27 cents per share.

* Revenue fell 1.3% to $151.65 million from a year ago; analysts expected $158.63 million.

* 10X Genomics Inc's reported EPS for the quarter was a loss of 30 cents​.

* The company reported a quarterly loss of $35.75 million.

* 10X Genomics Inc shares had fallen by 29.8% this quarter and lost 71.7% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 8.2% in the last three months.​

* In the last 30 days, five analysts negatively revised earnings estimates

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 9 "hold" and 1 "sell" or "strong sell."

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for 10X Genomics Inc is 22.50 This summary was machine generated from LSEG data October 30 at 02:49 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.34 -0.30 Beat

Jun. 30 2024 -0.48 -0.32 Beat

Mar. 31 2024 -0.50 -0.50 Met

Dec. 31 2023 -0.36 -0.41 Missed